Epithelioid Fibrous Histiocytoma: A Concise Review

Am J Dermatopathol. 2019 Dec;41(12):879-883. doi: 10.1097/DAD.0000000000001272.

Abstract

Epithelioid fibrous histiocytoma (EFH) is a rare lesion believed to arise from dermal microvascular unit fibroblasts and dendritic histiocytes. EFH has long been considered a morphologic variant of benign fibrous histiocytoma (dermatofibroma), with prominent epithelioid cytomorphology that can mimic both vascular and melanocytic neoplasms. The molecular basis for the relationship between EFH and benign fibrous histiocytoma has remained largely unknown, with some authors suggesting that EFH represents an entity that is biologically distinct from benign fibrous histiocytoma. Recent molecular studies have identified the presence of recurrent anaplastic lymphoma kinase (ALK) gene rearrangements, a phenomenon that has not been described in benign fibrous histiocytoma. These new molecular findings highlight the uniqueness of this rare tumor and may prove useful as a diagnostic tool for differentiation from other histologic mimics.

Publication types

  • Review

MeSH terms

  • Anaplastic Lymphoma Kinase / genetics
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics
  • Diagnosis, Differential
  • Epithelioid Cells / chemistry
  • Epithelioid Cells / pathology*
  • Gene Fusion
  • Gene Rearrangement
  • Genetic Predisposition to Disease
  • Histiocytoma, Benign Fibrous / chemistry
  • Histiocytoma, Benign Fibrous / genetics
  • Histiocytoma, Benign Fibrous / pathology*
  • Humans
  • Phenotype
  • Predictive Value of Tests
  • Prognosis
  • Soft Tissue Neoplasms / chemistry
  • Soft Tissue Neoplasms / genetics
  • Soft Tissue Neoplasms / pathology*

Substances

  • Biomarkers, Tumor
  • ALK protein, human
  • Anaplastic Lymphoma Kinase